Northwest Biotherapeutics; JAMA Oncology A Publication Journal of the American Medical Association Publishes Peer Reviewed Article on DCVax-L (murcidencel).
Overview
This article puts into perspective the importance of a peer reviewed article on the Phase 3 Trial of murcidencel (better known as DCVax-L) that was published today in JAMA Oncology, A publication of the Journal of the American Medical Association. This is a landmark event in which independent experts in an exhaustive process (which I will shortly describe) resoundingly validated previously reported clinical study findings. Here is the link to the article. The major findings presented in the JAMA Oncology article are consistent with those presented at the New York Academy of Sciences on May 10, 2022 although there is much more supporting information and analysis. The importance is that the article has been peer reviewed by both editors at JAMA and independent peer reviewers who validate that the trial was successful in showing that murcidencel increases survival in both newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM patients). Here is the conclusion of the JAMA article.
“This phase 3, nonrandomized, externally controlled trial found that the addition of DCVax-L to SOC was associated with a clinically meaningful and statistically significant extension of overall survival in both nGBM and rGBM. Treatment with DCVax-L also had an excellent safety profile and noteworthy tails of long-term survival curves.”
This does not assure that regulatory agencies will approve the drug but it should dramatically increase the confidence of analysts and investors that it could gain regulatory approval. Ladies and gentlemen, this is a huge positive.
About JAMA
JAMA Oncology is an international peer-reviewed medical journal published by the American Medical Association JAMA articles have been published continuously since 1883. As judged by impact with health care professionals, JAMA is one of the top four medical journals in the world along with The Lancet, New England Journal of Medicine and The British Medical Journal. JAMA is the most widely circulated general medical journal in the world, with more than 290,000 recipients of the print journal, more than 1.6 million recipients of electronic tables of contents and alerts, and over 38 million annual visits to the journal's website. JAMA's reach includes a social media presence with more than 982,000 followers on Twitter and Facebook and vast international news media exposure.
The Peer Review Process is Exhaustive
JAMA's acceptance rate for articles is 10% of the more than 11,000 annual submissions and 4% of the more than 6,000 research papers received (like that for murcidencel). Selection of an article for publication indicates that JAMA believes that it is a significant medical advance. All research articles submitted to JAMA are first reviewed by an in-house team of expert editors. A high proportion of research papers, are rejected on the basis of in-house assessment alone. If editors wish to proceed with a paper, they then select appropriate independent peer reviewers. A research article is usually peer reviewed by three or more clinical or subject-based experts and one or more statistical reviewers. The peer review process works to improve submitted articles while preventing any overstating of results from reaching physicians and the public.
Peer reviewers make suggestions for improvements, critique the analysis, and provide recommendations to the authors and the editors. Each published JAMA manuscript, then, benefits from hundreds of hours of work by editors, independent physician experts, statistical experts, manuscript editors, illustrators, proofreaders, and production personnel, who work to ensure that every paper meets exacting standards. It is an intensive interaction between the reviewers and the Company. The collective aim is to present the information in the most balanced and informative way. NWBO management has remarked that the peer review process was intense and beneficial in making the article the best that it could be.
Tagged as JAMA peer reviewed article on DCVax-L + Categorized as LinkedIn, Smith On Stocks Blog